title: Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
abstract: PET is a potentially useful modality for response analysis and prognosis prediction in patients with high-grade non-Hodgkin lymphoma (NHL). The thymidine analog 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) was recently introduced as a new tracer. (18)F-FLT uptake correlates with tumor cell proliferation and is suggested to reflect early response to treatment. We performed a prospective study to evaluate the prognostic value of early interim (18)F-FLT PET in patients with NHL.
  
  
  METHODS
  Patients with untreated NHL were enrolled between 2005 and 2007. Among them, 61 pairs of (18)F-FLT PET images were obtained at baseline (pre), after 1 cycle of chemotherapy (interim), and at the end of all scheduled first-line chemotherapy (final). All (18)F-FLT PET scans were interpreted by quantitative methods (maximum standardized uptake value [SUV max] and mean standardized uptake value [SUV mean]). Receiver-operating-characteristic curve analysis was performed to define (18)F-FLT PET positivity using a cutoff value predicting disease progression, relapse, or death. Survival outcome was measured by progression-free survival (PFS) and overall survival (OS) rates.
  
  
  RESULTS
  Receiver-operating-characteristic curve analysis of SUV max for prediction of disease progression and death showed the highest area under the curve (AUC) in interim (18)F-FLT PET scans (AUC of 0.841 for PFS and 0.834 for OS, with a cutoff of 1.86; P < 0.001), compared with pre and final (18)F-FLT PET scans. The SUV mean in interim (18)F-FLT PET scans also showed better prediction (AUC of 0.842 for PFS and 0.824 for OS, with a cutoff value of 1.65; P < 0.001) than pre and final (18)F-FLT PET scans. Patients with an interim (18)F-FLT PET SUV max more than 1.86, who were defined as the interim PET-positive group, were associated with worse 5-y PFS and OS rates than the interim PET-negative group (for PFS: 52.0% vs. 80.7%, respectively, and P < 0.001; for OS: 56.2% vs. 81.4%, respectively, and P < 0.001). By multivariable analysis, the prognostic value of interim (18)F-FLT PET positivity by SUV max remained significant after adjustment with other prognostic factors (for PFS: hazard ratio, 7.82, 95% confidence interval, 1.65-36.96, and P = 0.009; for OS: hazard ratio, 5.55, 95% confidence interval, 1.47-33.77, and P = 0.014).
  
  
  CONCLUSIONS
  In patients with aggressive NHL, early interim (18)F-FLT PET is a significant predictor of PFS and OS. Early (18)F-FLT PET imaging also has a potential to identify patients with delayed response and nonfavorable prognosis despite achieving a clinical complete response.
authors.affiliation: Hematology-Oncology Clinic, National Cancer Center, Goyang, South Korea.
authors.forename: Hyewon
authors.initials: H
authors.lastname: Lee
authors.forename: Seok-ki
authors.initials: SK
authors.lastname: Kim
authors.forename: Yong-il
authors.initials: YI
authors.lastname: Kim
authors.forename: Tae Sung
authors.initials: TS
authors.lastname: Kim
authors.forename: Se Hun
authors.initials: SH
authors.lastname: Kang
authors.forename: Weon Seo
authors.initials: WS
authors.lastname: Park
authors.forename: Tak
authors.initials: T
authors.lastname: Yun
authors.forename: Hyeon-Seok
authors.initials: HS
authors.lastname: Eom
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D018450:Disease Progression; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D011446:Prospective Studies; D012372:ROC Curve; D012008:Recurrence; D013941:Thymine / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D019788:Fluorodeoxyglucose F18; C032448:6-fluorothymine; D013941:Thymine
keywords: 18F-FLT; non-Hodgkin lymphoma (NHL); positron emission tomography (PET); prognosis; standardized uptake value